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Reciprocal balance of hepatocyte growth factor and trans- lesions provoke pathophysiological conditions in affected
forming growth factor-b1 in renal fibrosis in mice. tissues, eventually leading to clinical manifestation of
Background. Transforming growth factor-b1 (TGF-b1) plays abnormalities in the form of organ failure. Transforminga central role in the pathogenesis of renal fibrosis. In contrast,
growth factor-b1 (TGF-b1) is a pathogenic mediator inhepatocyte growth factor (HGF) may be an important molecule
tissue fibrosis in distinct organs [1–3]. TGF-b1 promotesfor tissue repair. As TGF-b1 is a suppressor molecule for HGF
expression, we asked whether a decrease in HGF expression ECM production, suppresses proteolytic breakdown of
would be accompanied by an increase in TGF-b1 and whether ECM proteins, and induces epithelial cell growth arrest
the progression of renal fibrosis would be modulated.
and apoptosis. The inhibition of TGF-b1 production orMethods. We used the ICR strain-derived glomerulonephri-
of its action attenuated progression of fibrosis in severaltis (ICGN) mice as a model of chronic renal disease and exam-
ined changes in local HGF expression during the natural course organs [4–6]. Increased expression of TGF-b1 in tissues
of renal fibrosis. To determine the significance of intrinsic HGF was noted in patients with fibrotic diseases, as well as in
noted during progression of renal fibrosis, we administered an experimental animals with fibrosis-related disorders.anti-HGF antibody to mice at the early stage of renal fibrosis.
Hepatocyte growth factor (HGF) was identified andResults. At an early stage of renal fibrosis, the mice showed
cloned as a potent mitogen for mature hepatocytes [7, 8].strong peritubular HGF expression, coinciding with tubular
proliferation. In the late stages, the renal HGF level was mark- Far beyond the implications of its name, HGF targets a
edly decreased, coinciding with a reduction in proliferative wide variety of cells and may function as a tissue orga-
tubular areas. Renal TGF-b1 levels were increased in accor- nizer by eliciting mitogenic, motogenic, and morphogenicdance with expansion of fibrotic areas. Notably, the anti-HGF
activities [9–11]. HGF is critically involved in embryo-antibody treatment of early-stage mice decreased the HGF
level and reduced tubular areas, whereas collagen-deposited genesis and organogenesis [12–14]. Additionally, the ad-
areas were expanded in parallel with increased TGF-b1 levels. ministration of exogenous HGF accelerates tissue repair
Consequently, in HGF-neutralized mice, there was a rapid in several organs after acute injury or ischemia [15–17].
progression of renal dysfunction.
Importantly, HGF prevents or attenuates the progres-Conclusions. Not only an increase in TGF-b1 level, but also
sion of liver cirrhosis [18, 19] and pulmonary fibrosisa decrease in local HGF expression may be responsible for the
manifestation of renal fibrosis, particularly tubular destruction. [20]. Therefore, HGF is a promising candidate as an
organotrophic factor accelerating tissue repair.
It is noteworthy that TGF-b1 suppressed expression
Fibrotic diseases include hepatic cirrhosis, pulmonary of HGF in several types of cells [21–24], whereas an
fibrosis, renal fibrosis and atherosclerosis, among others, anti–TGF-b1 antibody markedly improved impaired
and are histologically characterized by a progressive loss HGF production [25]. Therefore, TGF-b1 is a potent
of parenchymal cells and interstitial expansion with ex- negative regulator for HGF expression. HGF seems to
tracellular matrix (ECM) proteins. These irreversible have biological activities [9–11] that are opposite those
of TGF-b1: HGF stimulates renal tubular formation and
hepatic cellular proliferation [7–9], whereas TGF-b1 ar-Key words: chronic renal disease, tissue fibrosis, HGF, TGF-b, molecu-
lar pathogenesis. rests their growth [26, 27]. During renal tubular develop-
ment, the role(s) of HGF seems to be opposite that ofReceived for publication February 23, 1999
TGF-b1 [26]. HGF has a potent anti-apoptotic effectand in revised form October 11, 1999
Accepted for publication October 12, 1999 [15, 28], whereas TGF-b1 induces destructive changes
in parenchymal cells [1–3]. In addition, HGF releasesÓ 2000 by the International Society of Nephrology
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renal epithelial and endothelial cells from the growth fects of exogenous HGF, recombinant human HGF
(rhHGF) was purified from conditioned medium of Chi-arrest induced by TGF-b1 [29], whereas TGF-b1 causes
a marked inhibition of HGF-induced renal tubular mor- nese hamster ovary (CHO) cells transfected with expres-
sion vector containing HGF cDNA of the five aminophogenesis [30]. Based on in vitro findings, we speculated
that a reciprocal relationship may exist between TGF-b1 acids-deleted type [18, 20, 33].
and HGF at a local site and may modulate fibrotic lesions
Observations on the natural course of renal fibrosisin affected organs.
The ICR strain-derived glomerulonephritis (ICGN) Sixteen homozygous female ICGN mice were housed
under specific pathogen-free conditions and were pro-mice are a unique model of intractable nephrotic syn-
drome [31–33]. In the homozygous (that is, nephrotic) vided a standard diet (MF; Oriental yeast, Tokyo, Japan).
When eight mice were 12 to 16 weeks old and bloodmice, glomerular injury is histologically detectable from
three weeks after birth; however, renal dysfunction is urea nitrogen (BUN) levels began to rise (mean value 5
34.5 6 5.12 mg/dL), they were regarded as mice withnot obvious until the occurrence of interstitial fibrosis.
ICGN mice begin to show renal dysfunction from three early-stage renal fibrosis [31, 33]. When the remaining
eight mice were 22 to 28 weeks old and manifested clini-to four months after birth, and this dysfunction coincides
with tubular destruction and interstitial fibrosis. Consid- cal signs such as pale ears, anorexia, and body weight loss
accompanied with a significant elevation in BUN levelsering that renal dysfunction in patients with glomerular
diseases shows the best correlation with tubulointerstitial (64.5 6 10.8 mg/dL), they were regarded as mice with
the late-stage renal fibrosis [31]. At necropsy, they werefibrosis rather than with glomerulosclerosis, the ICGN
mice can save as an appropriate model for pathophysio- anesthetized with pentobarbital sodium (50 mg/kg, intra-
peritoneally), and serum and renal tissues were collectedlogical studies on human chronic renal diseases. While
the mutated gene has not been identified, inheritance of for biochemical or pathological analyses.
albuminuria in the nephrotic mice may perhaps be medi-
Anti-hepatocyte growth factor antibody treatmentated through a single autosomal recessive mutation [31].
In the present study, we focused on relationships be- For the anti-HGF IgG treatment, another 12 female
homozygous (that is, nephrotic) ICGN mice were gener-tween HGF and TGF-b1 expression during development
of fibrotic lesions in the kidney, especially in tubulointer- ated in our institute. When BUN levels in 12- to 16-
week-old mice slightly increased, and at the early-stagestitial spaces. Using the nephrotic ICGN mice as a model
relevant to renal fibrosis, we obtained evidence that a renal fibrosis, they were randomly divided into two
groups and intraperitoneally injected with the rabbitreciprocal balance between TGF-b1 and HGF at the site
of chronic renal injury may be associated with the manifes- anti-rat HGF IgG (250 mg per mouse, N 5 6) or normal
rabbit IgG (250 mg per mouse, N 5 6) on alternate daystation of fibrotic lesions. We propose that the decrease
in HGF, as well as the increase in TGF-b1, may be an over a period of eight days. These mice were sacrificed
on day 10 after the start of this treatment.important molecular event affecting the progression of
renal fibrosis.
Administration of exogenous hepatocyte growth factor
For administration of rhHGF, 16 female ICGN mice
METHODS
with the early-stage renal fibrosis (12 to 16 weeks of age)
Animals and reagents were randomly divided into two groups of eight mice
each. Mice in the experimental group were given a dailyThe ICGN mice were prepared by mating homozygous
(nep/nep; nephrotic) male and heterozygous (nep/2; intraperitoneal administration of rhHGF (500 mg/kg/day,
N 5 8) for a four week period, whereas mice in thenon-nephrotic) females [31–33]. The littermates were
considered nephrotic when albuminuria was detected, control mice were given intraperitoneal injections of an
identical volume of saline (N 5 8). We then examinedas described previously [31–33]. For HGF-neutralizing
treatment, an anti-HGF antibody was raised by immuniz- the effect of rhHGF injections on renal endogenous HGF
expression, collagen metabolism, and tubular apoptoticing rat HGF in normal rabbits [13, 14, 34, 35], and the
IgG fraction was purified using Protein A-Sepharose and proliferative changes, using the nephrotic model.
(Pharmacia Biotech, Uppsala, Sweden). This anti-rat
Histology and immunohistochemistryHGF antibody cross-reacts with mouse HGF, but not
with human HGF. The antibody inhibits branching tubu- Renal tissues obtained at necropsy were fixed in cold
70% ethanol for 12 to 24 hours and were embedded inlogenesis in fetal kidneys [13], as well as in lungs [14],
and modulates liver phenotypes in HGF-overexpressing paraffin. Tubular injury was evaluated on sections stained
with hematoxylin and eosin, and the degree of injury wastransgenic mice [35]. One microgram of anti-rat HGF
IgG neutralizes biological activity of at least 5 ng of semiquantitated, as scored elsewhere [31, 33]. Interstitial
inflammation was evaluated by infiltration of mononu-mouse HGF [34, 35]. To evaluate the cytoprotective ef-
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clear cells and was semiquantitated with a mononuclear antibody, the same ELISA kit was used, except that the
procedure for treatment with the second antibody wascell score, as described previously [31]. To visualize the
expression of growth factors, rabbit IgG against porcine omitted.
Furthermore, renal TGF-b1 levels were determinedpan-TGF-b (1:50; R&D Systems, Minneapolis, MN,
USA) [33] and rabbit IgG against rat HGF (1:1000; pre- in an ELISA system using a commercial kit (Quantikine
TGF-b1; R&D Systems) [33].pared in our laboratory [13, 14]) was used for the primary
reactions, and an avidin-biotin coupling (ABC) tech-
Statistical analysesnique was performed on the sections, together with a
commercial kit (Vectastain Elite; Vector Laboratories, All data examined were expressed as mean 6 SD. An
unpaired two-tailed t-test or Mann–Whitney U-test wasBurlingame, CA, USA). To identify myofibroblasts and
proliferating tubular cells, a monoclonal antibody against used to compare group means. Multiple linear regression
analyses were used to evaluate significance of the rela-human a-smooth muscle actin (a-SMA; Dako, Glostrup,
Denmark) and one against proliferating cell nuclear anti- tionship between variables. Values of P , 0.05 were
considered to be statistically significant.gen (PCNA; Dako) was used, respectively. To examine
the extent of interstitial fibrosis, rabbit IgG against rat
type I collagen (1:200; Cosmo-Bio, Tokyo, Japan) was
RESULTS
used for the primary reactions, followed by the ABC
Changes in local HGF and TGF-b1 levels duringperoxidase technique. To detect apoptotic cells, an in
renal fibrosissitu end-labeling method was used for dewaxed sections,
using a kit (TACM TdT system; Trevigen Inc., Gaithers- In the nephrotic ICGN mice, we initially examined
the renal expression of endogenous TGF-b1 and HGFburg, MD, USA). PCNA and apoptotic indices were
determined by counting at least 1000 proximal tubular during the natural course of renal fibrosis. Immunohisto-
chemical analyses revealed that TGF-b1–positive tubu-cells. Immunoreactive signals for a-SMA and for type I
collagen were observed in a blind fashion in at least lointerstitial cells were frequent in the late-stage of renal
fibrosis (Fig. 1A). The TGF-b–positive cells were de-20 randomly chosen non-overlapping high-power field
(3400) and were scored based on the scale of 0 (absent), tected mainly in the tubulointerstitial and periglomerular
areas, as described previously [33]. TGF-b–positive cells1 (mild), 2 (moderate), and 3 (severe) [36]. The overall
mean scores were calculated based on individual values, were fewer in early stage fibrosis but were more frequent
in mice in the late-stage fibrosis. In addition, tubularwhich were determined on at least 20 fields per mouse.
expression of TGF-b was mild not only in the early
Biochemical studies stage but also in the late-stage renal tissue. In contrast,
expression patterns of endogenous HGF were oppositeBlood urea nitrogen and serum creatinine levels were
measured to estimate renal function, as described else- those for TGF-b: HGF-positive labeling was strong but
mainly in fibroblastic cells, especially around intact tubu-where [31–33]. Urinary albumin level was determined
by a bromo-cresol green method using an A/G B-test kit lar components, in the early-stage fibrotic mice. In the
late-stage renal fibrosis, however, the number of HGF-(Wako, Osaka, Japan) [31–33]. The collagen level and
collagenase activity in the renal extract were measured by positive cells decreased, and the interstitial space was
occupied by myofibroblasts, identified as spindle-shapeda dye-binding method (Sircol collagen assay kit; Biocolor
Ltd., Belfast, Ireland) and by a fluorescence assay (type I cells with positive staining for a-SMA. Consequently,
interstitial fibrotic areas, identified as deposition of colla-collagenase activity kit; Cosmo-Bio), respectively.
gen, were more extensive in the late-stage fibrotic mice.
ELISA for hepatocyte growth factor and transforming Consistent with the immunohistochemical findings, re-
growth factor-b1 nal TGF-b1 levels, determined using an ELISA system,
in the late-stage fibrotic mice were much higher than inRenal tissue extract and plasma were obtained, as
described previously [37], and endogenous mouse HGF the early-stage fibrotic mice, whereas renal HGF levels
were significantly decreased in the late-stage fibroticwas measured using a sandwich enzyme-linked immuno-
sorbent assay (ELISA) kit (Institute of Immunology, mice, as compared with findings in the early-stage fibrotic
mice (45.0 6 25.6 ng/g · tissue vs. 205.2 6 53.8 ng/g ·Tokyo, Japan) [37]. The ELISA kit is composed of anti-
HGF monoclonal antibody (first antibody; cross-reactive tissue, P , 0.001; Fig. 1B). In the late-stage fibrotic mice,
the soluble collagen level was 3.3-fold higher than in theto both mouse and human HGF), rabbit anti-rat HGF
polyclonal antibody (second antibody; reactive to mouse early-stage mice. In a manner reciprocal to the accumula-
tion of collagen, renal collagenase activity in the late-HGF but not human HGF), and goat peroxidase-conju-
gated antirabbit IgG (third reagent). This ELISA kit stage mice was reduced to 31% of that found in the
early-stage mice.does not detect human HGF [37]. For measurement of
mouse HGF complexed with the neutralizing anti-HGF Further immunohistochemistry revealed that the tu-
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Fig. 1. Changes in renal phenotypes during the early and late stages of renal fibrosis in nephrotic ICGN mice. (A) Immunohistochemical findings
of endogenous transforming growth factor-b (TGF-b) and hepatocyte growth factor (HGF) (magnifications 3260) and those of a-smooth muscle
actin (a-SMA) and type I collagen (magnifications 3220) in early- and late-stage renal fibrosis. (B) Renal tissue levels of TGF-b1, HGF, and
soluble collagen level, and collagenase activity in early- and late-stage fibrosis. (C) Apoptotic and proliferative changes in renal tubules between
these stages of renal fibrosis (magnifications 3220). Abbreviations are discussed in the text. Data are expressed as mean 6 SD (N 5 8). *P , 0.05;
**P , 0.01; ***P , 0.001 compared with the early-stage group.
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Fig. 2. Scattergraphs showing correlations between renal fibrotic or compensatory events and local TGF-b1 or HGF levels during the natural
course of renal fibrosis. (A) Correlation between renal soluble collagen level and renal TGF-b1 or HGF levels. (B) Correlation between renal
collagenase activity and TGF-b1 or HGF levels. (C) Links of interstitial immunostaining score for a-SMA to TGF-b1 or HGF levels. (D)
Relationships between the tubular apoptotic index and TGF-b1 or HGF levels. (E) Relationships between the tubular PCNA index and TGF-b1
or HGF levels. Multiple linear regression analyses were undertaken in these scattergraphs for evaluating the significance of the relationship between
renal phenotypic markers (N 5 16: early stage, N 5 8, and late stage, N 5 8). Symbols are: (h) renal TGF-b1 level; (s) renal HGF level.
bular apoptotic cells were numerous in late-stage fibrotic level showed opposite patterns in the scattergraphs, as
was the case for the TGF-b1 level. The HGF levelmice: The proximal apoptotic index at the late-stage of
renal fibrosis showed a 2.2-fold increase over that at the showed a positive correlation with collagenase activity
and proximal PCNA index but negatively correlated withearly stage (8.14 6 1.46 vs. 3.76 6 1.27, P , 0.001; Fig.
1C). In contrast, proliferating tubular cells, identified as the collagen level, a-SMA score, and apoptotic index.
When comparing the renal HGF level in nephrotic micethe PCNA-positive nucleus, were frequent in proximal
tubular areas in the early-stage fibrosis, and the tubular with that of age-matched heterozygous (non-nephrotic)
littermates, the level in early-stage nephrotic mice wasPCNA index was significantly higher in early-stage than
in late-stage mice (7.81 6 1.38 vs. 3.49 6 1.14). significantly higher than that in the age-matched non-
nephrotic mice (205.2 6 53.8 ng/g vs. 133.5 6 23.6 ng/g,
Relationship between HGF or TGF-b1 level and P , 0.01). In contrast, renal HGF levels in late-stage
pathological phenotypes fibrotic mice were much lower than in the age-matched
non-nephrotic mice (45.0 6 25.6 ng/g vs. 125.2 6 33.8As shown in Figure 2, the TGF-b1 level correlated
ng/g; P , 0.01).positively with the soluble collagen level, interstitial
a-SMA score, and tubular apoptotic index (Fig. 2 A, C,
Aggravation of renal dysfunction and morphologyD) but was negatively linked to the collagenase activity
after HGF neutralizationand PCNA index (Fig. 2 B, E). Considering the role of
TGF-b1 in tissue fibrosis [1–6], TGF-b1 seems to corre- To determine whether decreased HGF expression
could cause or only reflect renal fibrosis, we injectedlate with fibrosis in our mouse model. The renal HGF
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Fig. 3. Influence of neutralizing treatment with an anti-HGF antibody (a-HGF) on renal function and morphology in nephrotic ICGN mice. (A)
Changes in BUN and serum creatinine levels for normal IgG ( ) and a-HGF (j). (B) Morphological changes in the renal cortex areas (hematoxylin
and eosin; magnification 3110). Data are expressed as mean 6 SD (N 5 6). **P , 0.01 compared with normal IgG-injected group.
neutralizing anti-HGF rabbit IgG (or normal rabbit IgG severe in mice given anti-HGF IgG than in the normal
as a placebo) into nephrotic mice with early-stage renal IgG-injected mice (Fig. 3B). The tubular injury score
fibrosis and examined effects on renal phenotypes. The was significantly higher in the anti-HGF IgG-treated
BUN level on day 10 in mice given anti-HGF IgG was mice than that in the control mice (3.00 6 1.09 vs. 1.33 6
1.6-fold higher than that of control mice given normal 0.86; P , 0.01). Mononuclear cell infiltration score in
IgG (56.8 6 15.6 vs. 35.4 6 4.24 mg/dL; P , 0.01; Fig. the HGF-neutralized mice was 2.8-fold higher than in
3A). Likewise, serum creatinine level in mice given the the normal IgG-injected mice (1.22 6 0.36 vs. 0.43 6
anti-HGF IgG was 1.8-fold higher than that of the pla- 0.26; P , 0.05). These findings strongly suggest that anti-
cebo-injected mice (P , 0.01). The urine albumin level HGF IgG treatment of the nephrotic mice accelerated the
was higher in the HGF-neutralized nephrotic mice than progression of renal dysfunction and tubular destruction.
in the placebo-injected mice (19.3 6 4.2 mg/dL vs. 29.1 6
Induction of TGF-b1 dominant in nephrotic kidneys4.5 mg/dL; P 5 0.079). Renal histopathology revealed
by HGF neutralizationthat the administration of anti-HGF IgG aggravated the
renal morphology. Tubular lesions (such as tubular epi- To obtain clues as to how HGF neutralization aggra-
vates renal fibrosis, we examined HGF and TGF-b1 ex-thelial atrophy with interstitial expansion) were more
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Fig. 4. Changes in endogenous HGF and TGF-b expressions in nephrotic ICGN mice by neutralizing treatment with an anti-HGF antibody
(a-HGF). (A) Immunohistochemical findings related to HGF (arrowheads; magnification 3260) and renal HGF concentrations in mice given
normal or anti-HGF IgG. (B) Immunostainings for TGF-b (arrowheads; magnification 3260) and renal TGF-b1 levels in mice given normal or
anti-HGF IgG. Data are expressed as mean 6 SD (N 5 6). *P , 0.05; **P , 0.01 compared with normal IgG-injected group.
pressions. When the renal HGF protein level was mea- Effects of HGF neutralization on tubular proliferation,
sured by ELISA [37], the total renal HGF level in mice apoptosis, and tubulointerstitial fibrosis
given anti-HGF IgG was lower than in the normal IgG- Tubular immunohistochemistry revealed that HGF
injected control mice (157.0 6 25.6 vs. 242.5 6 79.5 ng/g; neutralization reduced tubular proliferative areas but
P , 0.05). HGF complexed with the anti-HGF IgG in increased apoptotic changes (Fig. 5A). The number of
the kidney of the ICGN mice was 67.2 6 10.8 ng/g tissue. PCNA-positive proximal tubular cells in the nephrotic
Thus, 42% of total HGF was complexed with the neu- mice given anti-HGF IgG was reduced to 33% of that in
tralizing IgG, suggesting that significant parts of total
placebo-injected mice, whereas the number of apoptotic
HGF were neutralized by the antibody. Consistent with
tubular cells increased to a 1.9-fold higher level. In inter-the ELISA evidence of a decrease in renal HGF levels,
stitial areas, numerous myofibroblasts were noted in therenal immunohistochemistry revealed that interstitial HGF
HGF-neutralized mice, and the staining score for a-SMAexpression was weaker in the anti-HGF IgG group than
expression indicated an increase in myofibroblasts within the placebo group (Fig. 4A). Furthermore, the injec-
anti-HGF IgG treatment (Fig. 5B). Consistent with thesetion of anti-HGF IgG led to an increase in the number
molecular and cellular events, collagen-deposited areasof TGF-b–positive interstitial cells (probably including
in the interstitial space expanded: Staining score for type Imacrophages) and, in part, increased tubular TGF-b ex-
collagen in the anti-HGF IgG-treated mice was muchpression (data not shown). As a result, the TGF-b1 level
higher than that in the control mice (2.23 6 0.40 vs. 0.57 6in the HGF-neutralized kidney increased to a 2.4-fold
level over that in the placebo control (Fig. 4B). 0.18; P , 0.01). Renal collagenase activity was reduced
Fig. 5. Aggravation of tubular apoptosis and interstitial fibrotic events after anti-HGF (a-HGF) IgG treatment. (A) Immunohistochemical findings
of tubular proliferation and of apoptosis (magnifications 3220) and a semiquantitative analysis using PCNA and apoptotic indices. (B) Interstitial
myofibroblast formation and type I collagen deposition (magnifications 3220) and semiquantitation, as determined by a-SMA and type I collagen
scores. (C) Modulations of renal collagenase activity and collagen level by anti-HGF treatment. Data are expressed as mean 6 SD (N 5 6). *P ,
0.05; **P , 0.01; ***P , 0.001 compared with the normal IgG-injected control group.
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Fig. 6. Antifibrotic and anti-apoptotic effects of exogenous HGF on renal tissues in the nephrotic ICGN mice. (A) Changes in the endogenous
HGF level, renal collagenase activity, and the soluble collagen level by rhHGF administration. (B) Representative findings of tubular apoptotic
changes (magnification 3260) and apoptotic index. Data are expressed as mean 6 SD (N 5 8). ***P , 0.001 compared with the saline-injected
control group.
after anti-HGF IgG-treatment, whereas the renal colla- enhanced with rhHGF injections, and the soluble colla-
gen level in the anti-HGF IgG-treated mice was signifi- gen level in the HGF-injected mice was reduced to only
cantly higher than that in the control mice (Fig. 5C). 21% of that in control mice. With regard to tubular
events, apoptotic changes were markedly suppressed in
Inhibition of ECM deposition and tubular apoptosis the rhHGF-injected mice (Fig. 6B), whereas rhHGF in-
with rhHGF administration jection increased the PCNA index to a 2.7-fold level of
We also designed an opposite experiment: Nephrotic saline-injected control ICGN mice (7.76 6 2.15 vs. 2.80 6
ICGN mice were given either rhHGF or saline for a four 0.58, P , 0.01).
week period. The rhHGF injections increased endoge-
nous HGF level in the kidney to a 6.5-fold higher level
DISCUSSIONthan that found in the saline-injected control mice (Fig.
To develop an appropriate strategy for treatment of6A), findings consistent with previous in vitro results that
fibrosis-related diseases, molecular mechanisms wherebyexogenous HGF could increase endogenous HGF levels
fibrogenic events occur have to be addressed. It is widely[23, 25]. On the other hand, the renal TGF-b1 level in
accepted that TGF-b1 plays a key role in fibrogenesisthe HGF-injected mice was reduced to only 36% of the
as a premier molecule [1–6]. On the other hand, it hascontrol level (275.7 6 54.3 vs. 833.5 6 213.5 pg/g · issue,
P , 0.05). Renal collagenase activity was significantly been documented that HGF is strongly expressed around
Mizuno et al: HGF as an intrinsic repair factor in fibrosis946
or in parenchymal hyperplastic areas of several organs in the TGF-b1–dominant kidney (late-stage of renal fi-
brosis), whereas collagenase activity was high in theundergoing chronic injury, including lungs [38] and liver
[39, 40], occasionally concomitant with parenchymal PCNA HGF-dominant kidney (early stage of renal fibrosis).
Moreover, neutralization of HGF decreased renal colla-expression. However, it remains unclear whether endog-
enous HGF is associated with preventing or accelerating genase activity, whereas it was restored by exogenously
delivered HGF. Therefore, HGF may be associated withfurther progression of fibrosis. In the present work, we
found that neutralization of HGF accelerated the pro- the local activation of enzymes responsible for ECM
degradation, and this may allow for a decrease in ECMgression of renal fibrosis, accompanied by an increase in
TGF-b1 expression, whereas the addition of exogenous components in nephrotic kidneys, as was noted in the
fibrotic liver [18].HGF suppressed fibrogenic events accompanied by a
decrease in TGF-b1 expression. We also noted a recipro- It is of interest to note that HGF has antifibrotic effects
[18–20, 33], some of which may be generated throughcal relationship in expression and tissue levels between
HGF and TGF-b1: In the HGF-dominant kidney, TGF-b1 its angiogenetic activity [47]. In the present study, we
directed attention to non-vascular lesions because renalexpression was suppressed, and renal tissue underwent
compensatory growth without severe fibrosis, whereas dysfunction in patients with renal fibrosis correlates
more closely with the extent of tubular atrophy than itin the TGF-b1–dominant kidney, the local HGF level
was low and renal tissue showed fibrotic changes. Our does with that of glomerular and vascular lesions [46, 48].
However, the importance of non-tubular injuries cannotpresent findings suggest that endogenous HGF may pro-
tect nephrotic kidneys from fibrosis, whereas a decrease be excluded, because these lesions could be a causal
factor in renal fibrosis [46]. Indeed, anti-HGF IgG treat-in the renal HGF level may further aggravate renal fi-
brosis in the kidney. ment increased urine albumin excretion and accelerated
the progression of glomerular injury (unpublished obser-During the fibrotic process, a progressive loss in paren-
chymal cells occurs as a common cellular event. In the vations), whereas HGF injection prevented glomerular
deterioration and proteinuria [33]. Thus, the tubular at-progressively deteriorating kidney, compensatory growth
occurs in surviving nephrons [41]. HGF is a candidate rophy seen in anti-HGF IgG-treated mice may be partly
generated through glomerular injury and proteinuria,renotropic factor [16, 42–45] and is likely to be an impor-
tant molecule for compensatory growth in the injured although it is difficult to determine whether tubular de-
struction reflects or causes glomerular destruction, askidney. Indeed, serial injections of rhHGF to nephrotic
ICGN mice markedly enhanced and maintained com- described elsewhere [46].
One particular finding of interest is existence of thepensatory tubular proliferation [33]. In contrast to bio-
logical functions of HGF, TGF-b1 inhibits parenchymal reciprocal expression of HGF and TGF-b1 and its possi-
ble involvement in the pathogenesis of renal fibrosis.growth and induces degenerative changes in epithelial
cells [1–6]. In our nephrotic mice, tubular growth occurs This expression pattern of HGF and TGF-b1 has also
been noted in patients with liver cirrhosis [39, 40] andin the early stage in the form of hyperplasia [31]. How-
ever, in later stages during the natural course of renal a rat cirrhosis model [40]. Endogenous HGF is strongly
expressed around proliferative hepatocellular areas,fibrosis, tubular growth disappears in renal tissues, and
tubular apoptosis in turn becomes evident. Therefore, whereas TGF-b expression is evident around interstitial
cirrhotic lesions [39]. Considering the direct inhibitoryHGF seems to protect the injured kidney, probably by
preventing apoptotic cell death in renal epithelial cells effect of TGF-b1 on HGF expression [22–25], it is likely
that an increase in TGF-b1 expression suppresses local[28] as well as through inducing compensatory growth
[33] in intact tubular areas, especially in proximal tu- HGF production. Conversely, a reduction in HGF ex-
pression may lead to enhancement of the local expres-bules. Indeed, neutralization of HGF in the kidney un-
dergoing compensatory growth evoked tubular atrophy sion of TGF-b1, probably through an increase in the
number of inflammatory cells. Indeed, HGF plays a reno-accompanied with apoptosis, whereas the administration
of exogenous HGF to the nephrotic mice (wherein en- tropic role(s) in chronic tubular injury [33], and the de-
crease in this renotropic factor may aggravate furtherdogenous renal HGF level was low) suppressed tubular
cell death. tubular destruction, in addition to the increased protein-
uria, leading to an over-accumulation of inflammatoryIn addition to parenchymal cell death, connective tis-
sue accumulation in interstitial spaces is also a key event cells such as macrophages, an important source of
TGF-b1 in our model [33]. Furthermore, HGF also canin fibrosis because further tissue scarring could provoke
hypovascular changes, leading to an acceleration of renal directly suppress TGF-b1 production in a cell line of
stromal cells (J. Fujimoto et al, personal communication)destruction [46]. The extent of connective tissue forma-
tion is regulated through a balance between ECM pro- [19]. Therefore, HGF and TGF-b1 might, to some extent,
modulate their reciprocal expressions. In addition, an-duction and its degradation, which may be modulated
by TGF-b1. In our model, the collagen level was high giotensin II, another candidate as a mediator(s) of fibro-
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sis, suppresses HGF production [23]. Therefore, the sec- HGF addition prevents tissue fibrosis in the kidney and
ond mediator may more or less regulate a balance possibly in other organs such as the liver and lungs.
between HGF and TGF-b1.
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